Log in to search using one of your social media accounts:

 

Morphosys sees revenue boost as FDA approves psoriasis drug

DUESSELDORF/FRANKFURT (Reuters) - German biotech group Morphosys expects to receive royalties for its psoriasis drug guselkumab for five months this year, its Chief Executive Simon Moroney said, after its licensee received U.S. regulatory approval.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

30 November – 2 December 2017, London, United Kingdom
Source: Scientific and Medical Events on Global Events List - Category: Science Source Type: events
In this review, the International Psoriasis Council explains how biosimilars are evaluated in a clinical setting.The British Journal of Dermatology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Series Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThis SuperSeries is composed of the SubSeries listed below.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
Contributors : Rob van der Kammen ; Metello InnocentiSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusArp2/3 complex assembles branched actin filaments key to many cellular processes, but its organismal roles remain poorly understood. Here we employed conditional arpc4 knockout mice to study the function of the Arp2/3 complex in the epidermis.We found that depletion of the Arp2/3 complex by knockout of arpc4 results in skin abnormalities at birth that evolve into a severe psoriasis-like disease hallmarked by hyperactivation of transcription factor Nrf2. Knockout of arpc4 in cultured ke...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
Contributors : Rob van der Kammen ; Metello InnocentiSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusArp2/3 complex assembles branched actin filaments key to many cellular processes, but its organismal roles remain poorly understood. Here we employed conditional arpc4 knockout mice to study the function of the Arp2/3 complex in the epidermis.We found that depletion of the Arp2/3 complex by knockout of arpc4 results in skin abnormalities at birth that evolve into a severe psoriasis-like disease hallmarked by hyperactivation of transcription factor Nrf2. Knockout of arpc4 in cultured ke...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
We report a case of a 30‐year‐old Chinese woman with rheumatoid arthritis and interstitial lung disease who abruptly developed generalized pustules and a high fever for 10 days. She had been taking oral prednisone, iguratimod and total glucosides of peony regularly for 5 months prior. In addition, she had taken metronidazole for 3 days 20 days prior which she had used before with no adverse reaction. She had no history of similar lesions and psoriasis. A biopsy of a pustule on the back showed spongiform pustule of Kogoj. She was suspected of having generalized pustular psoriasis or acute generalized exanthematous pustu...
Source: The Journal of Dermatology - Category: Dermatology Authors: Tags: Concise Communication Source Type: research
Updated Date: Nov 22, 2017 EST
Source: DailyMed Drug Label Updates - Category: Drugs & Pharmacology Source Type: alerts
Psoriasis is an immune-mediated chronic inflammatory disease characterized by abnormal epidermal differentiation, hyperproliferation, angiogenesis, and increased T-cell infiltrates. As a chronic relapsing and remitting inflammatory skin disease, it affects approximately 1-3% of the population [1].
Source: Journal of Dermatological Science - Category: Dermatology Authors: Source Type: research
Source: British Journal of Dermatology - Category: Dermatology Authors: Tags: Research Letter Source Type: research
BackgroundTumor necrosis factor α (TNFα) blocking drugs are in use for a wide range of autoimmune disorders. In up to 5% of patients, this class of drugs produces puzzling cutaneous side effects that are the subject of this investigation, namely psoriasiform and eczema‐like skin inflammation. These side effects can occur after any time of treatment and regardless of the underlying disorders. The exact pathophysiology is as yet unknown. MethodsA total of 33 patients (19 female, average age 52 years) who had a cutaneous reaction to infliximab, adalimumab or etanercept were included. The type of inflammat...
Source: Journal of Cutaneous Pathology - Category: Pathology Authors: Tags: ORIGINAL ARTICLE Source Type: research
More News: Biotechnology | Germany Health | Health | Psoriasis